Dermata (NASDAQ: DRMA) investors approve equity plan expansion and warrant changes
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Dermata Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders, where all management proposals were approved. Stockholders amended the 2021 Omnibus Equity Incentive Plan to increase the maximum aggregate number of shares reserved for issuance under the plan to 402,214 shares.
They also approved, for Nasdaq Listing Rule 5635(d) purposes, the issuance of common shares underlying certain warrants in an amount equal to or in excess of 20% of the common stock outstanding immediately before those warrants were issued, as well as a repricing of warrants exercisable for up to 120,734 shares. Three Class II directors were elected, the independent auditor for the year ending December 31, 2026 was ratified, and an adjournment proposal was approved.
Positive
- None.
Negative
- Stockholders approved warrant-related proposals that permit issuing common shares underlying warrants equal to or exceeding 20% of previously outstanding stock and repricing warrants for up to 120,734 shares, which may materially increase the future share count if fully exercised.
Insights
Shareholders approved sizeable warrant-related issuances and repricing alongside equity plan expansion.
The meeting outcomes give Dermata Therapeutics flexibility to issue equity through its 2021 plan and through warrants. The plan reserve was raised to 402,214 shares, and warrant-related proposals tied to prior financing arrangements received stockholder approval.
The Issuance Proposal authorizes issuing common shares underlying warrants in an amount equal to or above 20% of pre-issuance outstanding stock under Nasdaq Listing Rule 5635(d). A separate proposal approved repricing warrants for up to 120,734 shares, which can affect future exercise behavior and share count. The actual impact depends on warrant exercises and equity grants over time.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares reserved under 2021 Plan: 402,214 shares
Shares represented at meeting: 2,374,471 common shares
Warrants subject to repricing: 120,734 shares
+3 more
6 metrics
Shares reserved under 2021 Plan
402,214 shares
Maximum aggregate number of shares reserved after plan amendment
Shares represented at meeting
2,374,471 common shares
Approximately 59% of outstanding common stock entitled to vote
Warrants subject to repricing
120,734 shares
Warrants exercisable for up to this number of common shares
Issuance threshold
20% of common stock
Issuance of warrant shares equal to or in excess of 20% of pre-issuance outstanding shares
Votes for Auditor Proposal
2,329,537 for, 43,122 against, 1,812 abstain
Ratification of CBIZ CPAs P.C. for year ending December 31, 2026
Votes for Plan Amendment Proposal
1,243,540 for, 47,441 against, 14,834 abstain
Amendment increasing 2021 Plan share reserve
Key Terms
Nasdaq Listing Rule 5635(d), 2021 Omnibus Equity Incentive Plan, warrant repricing, broker non-votes, +2 more
6 terms
Nasdaq Listing Rule 5635(d) regulatory
"for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of shares"
Nasdaq Listing Rule 5635(d) is a stock-exchange rule that determines when a company must get shareholder approval before issuing new shares tied to conversions or exercises of existing convertible securities, options or warrants. It matters to investors because it controls potential dilution of their holdings and changes in voting power—think of it like a rule that decides whether a previously agreed‑upon coupon can be redeemed without asking the group again.
2021 Omnibus Equity Incentive Plan financial
"amendment to the Company’s 2021 Omnibus Equity Incentive Plan (the “2021 Plan”)"
warrant repricing financial
"the approval of the repricing of warrants exercisable for up to 120,734 shares of Common Stock"
Warrant repricing is when a company lowers the price at which holders can buy shares using their existing warrants, making those warrants easier to exercise when the market price has fallen. It matters to investors because it can revive the value of those warrants (like reducing the price on a gift card so it can still be used) but also can dilute existing shareholders and change the company’s future fundraising and ownership dynamics.
broker non-votes financial
"For | | Against | | Abstain | | Broker Non-Votes 315,477"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"the ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Adjournment Proposal regulatory
"the approval of the adjournment of the Annual Meeting to the extent there are insufficient votes"
An adjournment proposal is a formal request made at a shareholder or board meeting to pause the meeting and reconvene at a later date or time. It matters to investors because it postpones votes and decisions, giving parties extra time to gather information, solicit support, negotiate alternatives or introduce new options — like hitting pause on a group decision to wait for more facts, which can alter outcomes and market reactions.
FAQ
How was Dermata Therapeutics’ 2021 Omnibus Equity Incentive Plan changed?
Stockholders approved an amendment increasing the maximum aggregate number of shares of common stock reserved for issuance under the 2021 Omnibus Equity Incentive Plan to 402,214 shares, providing additional capacity for future equity-based awards to directors, officers, employees, and other eligible participants under the plan.
What is Dermata’s Issuance Proposal under Nasdaq Listing Rule 5635(d)?
The Issuance Proposal approved issuing common shares underlying certain warrants in an amount equal to or in excess of 20% of the common stock outstanding immediately before those warrants were issued, satisfying Nasdaq Listing Rule 5635(d) requirements tied to prior financing and engagement arrangements.
Were Dermata’s auditor and directors approved by stockholders in 2026?
Yes. Stockholders elected David Hale, Steven Mento, Ph.D., and Brittany Bradrick as Class II directors to serve until the 2029 annual meeting, and ratified CBIZ CPAs P.C. as Dermata’s independent registered public accounting firm for the fiscal year ending December 31, 2026.